PRTG

Summary

PRTG (protogenin, HGNC:26373) is a protein-coding gene on chromosome 15q21.3, encoding Protogenin (Q2VWP7). May play a role in anteroposterior axis elongation.

This gene encodes a member of the immunoglobulin superfamily. The encoded transmembrane protein has been associated with the development of various tissues, especially neurogenesis. It has been suggested that this gene may be associated with attention deficit hyperactivity disorder (ADHD).

Source: NCBI Gene 283659 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 160 total
• MANE Select transcript: NM_173814

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26373
Approved symbol	PRTG
Name	protogenin
Location	15q21.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ25756, IGDCC5
Ensembl gene	ENSG00000166450
Ensembl biotype	protein_coding
OMIM	613261
Entrez	283659

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 1 retained_intron, 1 TEC

ENST00000389286, ENST00000558349, ENST00000559842, ENST00000561292, ENST00000561465, ENST00000623053

RefSeq mRNA: 1 — MANE Select: NM_173814 NM_173814

CCDS: CCDS42040

Canonical transcript exons

ENST00000389286 — 20 exons

Exon	Start	End
ENSE00001103077	55637170	55637340
ENSE00001103085	55628822	55629004
ENSE00001103098	55638549	55638676
ENSE00001184454	55624342	55624507
ENSE00001184459	55627008	55627128
ENSE00001184487	55620663	55620767
ENSE00001253055	55611544	55620266
ENSE00001505349	55639642	55639828
ENSE00001505350	55641113	55641208
ENSE00001505351	55672445	55672633
ENSE00001505352	55673371	55673676
ENSE00001505353	55675519	55675683
ENSE00001505354	55677797	55678044
ENSE00001505356	55679286	55679445
ENSE00001505357	55680054	55680212
ENSE00001505359	55680491	55680628
ENSE00001505360	55682364	55682497
ENSE00001536745	55683787	55683931
ENSE00001536748	55740382	55740684
ENSE00001536751	55742838	55743152

Expression profiles

Bgee: expression breadth ubiquitous, 193 present calls, max score 97.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.1884 / max 1561.5565, expressed in 1044 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
150134	20.6874	1024
150135	0.5722	143
150115	0.5438	102
150137	0.2905	100
150138	0.2887	89
150136	0.2105	86
150126	0.2068	62
150139	0.1823	91
150133	0.0981	52
150124	0.0586	34

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	97.85	gold quality
secondary oocyte	CL:0000655	96.25	gold quality
oocyte	CL:0000023	94.23	gold quality
sperm	CL:0000019	87.29	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.77	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.38	gold quality
endothelial cell	CL:0000115	82.83	gold quality
thyroid gland	UBERON:0002046	79.42	gold quality
left lobe of thyroid gland	UBERON:0001120	78.88	gold quality
right lobe of thyroid gland	UBERON:0001119	78.68	gold quality
pancreatic ductal cell	CL:0002079	77.93	silver quality
tibia	UBERON:0000979	77.74	gold quality
pigmented layer of retina	UBERON:0001782	77.36	gold quality
calcaneal tendon	UBERON:0003701	76.66	gold quality
placenta	UBERON:0001987	76.32	gold quality
oviduct epithelium	UBERON:0004804	75.02	gold quality
sural nerve	UBERON:0015488	74.58	gold quality
endometrium	UBERON:0001295	73.10	gold quality
tibialis anterior	UBERON:0001385	72.67	silver quality
cauda epididymis	UBERON:0004360	71.18	gold quality
colonic epithelium	UBERON:0000397	71.04	gold quality
adrenal tissue	UBERON:0018303	69.75	gold quality
visceral pleura	UBERON:0002401	68.92	gold quality
uterus	UBERON:0000995	68.50	gold quality
body of uterus	UBERON:0009853	68.30	gold quality
lower lobe of lung	UBERON:0008949	68.27	silver quality
tendon	UBERON:0000043	68.02	gold quality
medial globus pallidus	UBERON:0002477	67.96	silver quality
testis	UBERON:0000473	67.06	gold quality
cartilage tissue	UBERON:0002418	66.32	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-GEOD-75140	yes	860.27
E-MTAB-10018	yes	631.84
E-HCAD-56	yes	323.64
E-MTAB-9388	yes	10.15
E-ANND-3	yes	10.05
E-MTAB-8205	no	444.70
E-MTAB-8271	no	7.54

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

469 targeting PRTG, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-4476	100.00	68.18	2030

Literature-anchored findings (GeneRIF, showing 4)

• Identified association of attention deficit hyperactivity disorder (ADHD) to Protogenin (PRTG), a gene that potentially plays a role in cell migration and axon growth. (PMID:19076634)
• PRTG is regulated by miRNA9, plays an inhibitory action on survival of chondroblasts and articular chondrocytes during chondrogenesis and osteoarthritis pathogenesis. (PMID:24007463)
• We found that a burden of low-frequency coding variants in N4BP2, CDSN, PRTG, and AHRR were associated with increased risk of Nonsyndromic cleft lip with or without cleft palate (NSCL/P) . Low-frequency variants in other genes were associated with decreased risk of NSCL/P. These results demonstrate that low-frequency variants contribute to the genetic etiology of NSCL/P (PMID:28425186)
• The novel ZEB1-upregulated protein PRTG induced by Helicobacter pylori infection promotes gastric carcinogenesis through the cGMP/PKG signaling pathway. (PMID:33542225)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	prtga	ENSDARG00000100044
mus_musculus	Prtg	ENSMUSG00000036030
rattus_norvegicus	Prtg	ENSRNOG00000055251

Paralogs (36): CNTN1 (ENSG00000018236), CDON (ENSG00000064309), NEO1 (ENSG00000067141), SDK2 (ENSG00000069188), IGSF9B (ENSG00000080854), IGSF9 (ENSG00000085552), NRCAM (ENSG00000091129), MXRA5 (ENSG00000101825), IGDCC4 (ENSG00000103742), CNTN3 (ENSG00000113805), IGSF21 (ENSG00000117154), CNTN6 (ENSG00000134115), CHL1 (ENSG00000134121), PTPRQ (ENSG00000139304), CNTN4 (ENSG00000144619), BOC (ENSG00000144857), SDK1 (ENSG00000146555), HMCN2 (ENSG00000148357), NCAM1 (ENSG00000149294), CNTN5 (ENSG00000149972), IGSF10 (ENSG00000152580), ROBO4 (ENSG00000154133), ROBO3 (ENSG00000154134), NCAM2 (ENSG00000154654), VCAM1 (ENSG00000162692), NFASC (ENSG00000163531), ROBO1 (ENSG00000169855), DSCAM (ENSG00000171587), IGDCC3 (ENSG00000174498), VSIG10 (ENSG00000176834), DSCAML1 (ENSG00000177103), CNTN2 (ENSG00000184144), ROBO2 (ENSG00000185008), VSIG10L (ENSG00000186806), DCC (ENSG00000187323), L1CAM (ENSG00000198910)

Protein

Protein identifiers

Protogenin — Q2VWP7 (reviewed: Q2VWP7)

Alternative names: Protein Shen-Dan

All UniProt accessions (4): Q2VWP7, H0YKD6, H0YLD1, H0YLT7

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in anteroposterior axis elongation.

Subcellular location. Membrane.

Similarity. Belongs to the immunoglobulin superfamily. DCC family.

RefSeq proteins (1): NP_776175* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR003961	FN3_dom	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily

Pfam: PF00041, PF07679, PF13927

UniProt features (30 total): domain 9, compositionally biased region 4, disulfide bond 4, glycosylation site 3, sequence variant 3, region of interest 2, topological domain 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q2VWP7-F1	74.18	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (4): 60–113, 156–205, 256–304, 348–395

Glycosylation sites (3): 90, 488, 630

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 186 (showing top): GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, GOBP_NEGATIVE_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, GOBP_CELL_CELL_ADHESION, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, TGTGTGA_MIR377, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP, GOBP_REGULATION_OF_CELL_DEVELOPMENT, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, ATGTTTC_MIR494

GO Biological Process (2): negative regulation of neurogenesis (GO:0050768), cell-cell adhesion (GO:0098609)

GO Molecular Function (3): signaling receptor activity (GO:0038023), identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (3): obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
negative regulation of cell development	1
neurogenesis	1
regulation of neurogenesis	1
negative regulation of nervous system development	1
cell adhesion	1
molecular transducer activity	1
protein binding	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

748 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRTG	LRFN2	Q9ULH4	540
PRTG	DAZAP2	Q15038	480
PRTG	ERICH6B	Q5W0A0	413
PRTG	LRRC63	Q05C16	387
PRTG	N4BP2	Q86UW6	380
PRTG	CHMP4B	Q9H444	368
PRTG	NGF	P01138	359
PRTG	AMOTL1	Q8IY63	353
PRTG	KANSL3	Q9P2N6	349
PRTG	LIN28B	Q6ZN17	344
PRTG	CGNL1	Q0VF96	343
PRTG	VWC2	Q2TAL6	339
PRTG	IGSF11	Q5DX21	333
PRTG	TAL2	Q16559	325
PRTG	GUCY1A2	P33402	322

IntAct

24 interactions, top by confidence:

A	B	Type	Score
PRTG	ICAM5	psi-mi:“MI:0915”(physical association)	0.540
PRTG	WFIKKN2	psi-mi:“MI:0915”(physical association)	0.540
ICAM5	PRTG	psi-mi:“MI:0407”(direct interaction)	0.540
PRTG	WFIKKN2	psi-mi:“MI:0407”(direct interaction)	0.540
TMEM30B	KLRG2	psi-mi:“MI:0914”(association)	0.530
FCGRT	GOLIM4	psi-mi:“MI:0914”(association)	0.530
LGALS1	PODXL	psi-mi:“MI:0914”(association)	0.530
PRTG	LTF	psi-mi:“MI:0407”(direct interaction)	0.440
PRTG	IGFBPL1	psi-mi:“MI:0407”(direct interaction)	0.440
PRTG	IGFBP7	psi-mi:“MI:0407”(direct interaction)	0.440
HAPLN1	PRTG	psi-mi:“MI:0915”(physical association)	0.400
IL1RAPL2	PRTG	psi-mi:“MI:0915”(physical association)	0.400
LRRTM2	PRTG	psi-mi:“MI:0915”(physical association)	0.400
ISLR2	PRTG	psi-mi:“MI:0915”(physical association)	0.400
MICA	PRTG	psi-mi:“MI:0915”(physical association)	0.400
RIPK4	VWA8	psi-mi:“MI:0914”(association)	0.350
DISC1	AGRN	psi-mi:“MI:0914”(association)	0.350
GDF11	TSPY2	psi-mi:“MI:0914”(association)	0.350
NRSN1	FAM171A2	psi-mi:“MI:0914”(association)	0.350
RYK	TNFRSF10B	psi-mi:“MI:0914”(association)	0.350
MSTN	GDF11	psi-mi:“MI:0914”(association)	0.350

BioGRID (13): PRTG (Affinity Capture-MS), PRTG (Affinity Capture-MS), PRTG (Affinity Capture-MS), PRTG (Affinity Capture-RNA), PRTG (Affinity Capture-MS), PRTG (Affinity Capture-MS), PRTG (Affinity Capture-MS), PRTG (Affinity Capture-MS), PRTG (Affinity Capture-MS), PRTG (Affinity Capture-MS), PRTG (Affinity Capture-MS), PRTG (Affinity Capture-MS), RRP9 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A2A8L5, A4IFW2, A7MBJ4, B0V2N1, F1NWE3, O00533, O42414, O55005, O89026, O94856, O97394, P10586, P11627, P16621, P22063, P23468, P28685, P32004, P70232, P97685, P97686, Q02246, Q05695, Q13332, Q28902, Q2EY14, Q2EY15, Q2VWP7, Q2VWP9, Q3UH53, Q589G5, Q58EX2, Q61330, Q64487, Q64604, Q64605, Q6V4S5, Q7Z5N4, Q810U3, Q810U4

Diamond homologs: A2AAJ9, A2ABU4, O88599, P12960, P14781, P28685, P52179, P54296, P68500, P70402, P97527, P97528, Q02173, Q07409, Q12860, Q13203, Q14896, Q28106, Q2EY15, Q2VWP7, Q2VWP9, Q589G5, Q5PQM4, Q5VTT5, Q62234, Q62682, Q63198, Q7ZW34, Q86TB3, Q91ZB0, Q924C5, Q96JA1, Q96L96, Q98936, Q9P232, A0A452E9Y6, A1KZ92, A2ASS6, A4IGL7, A5JUY8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

160 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	138
Likely benign	8
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

3345 predictions. Top by Δscore:

Variant	Effect	Δscore
15:55625290:AAT:A	donor_gain	1.0000
15:55625315:AAC:A	donor_gain	1.0000
15:55627019:T:TA	donor_gain	1.0000
15:55627129:C:CC	acceptor_gain	1.0000
15:55637165:TTTA:T	donor_loss	1.0000
15:55637166:TTA:T	donor_loss	1.0000
15:55637167:TAC:T	donor_loss	1.0000
15:55637169:C:CA	donor_loss	1.0000
15:55637195:T:A	donor_gain	1.0000
15:55637336:TGGTG:T	acceptor_gain	1.0000
15:55637337:GGTG:G	acceptor_gain	1.0000
15:55637338:GTG:G	acceptor_gain	1.0000
15:55637339:TG:T	acceptor_gain	1.0000
15:55637341:C:CC	acceptor_gain	1.0000
15:55637343:G:C	acceptor_gain	1.0000
15:55637343:G:GC	acceptor_gain	1.0000
15:55637346:C:CT	acceptor_gain	1.0000
15:55637350:C:CT	acceptor_gain	1.0000
15:55638543:CTTTA:C	donor_loss	1.0000
15:55638544:TTTAC:T	donor_loss	1.0000
15:55638545:TTACC:T	donor_loss	1.0000
15:55638546:TACCT:T	donor_loss	1.0000
15:55638547:A:AT	donor_loss	1.0000
15:55638548:CCTT:C	donor_gain	1.0000
15:55638548:CCTTC:C	donor_loss	1.0000
15:55638672:CTGAT:C	acceptor_gain	1.0000
15:55638673:TGAT:T	acceptor_gain	1.0000
15:55638675:ATC:A	acceptor_loss	1.0000
15:55638676:TC:T	acceptor_loss	1.0000
15:55638677:C:CA	acceptor_loss	1.0000

AlphaMissense

7450 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:55628950:A:T	V893D	1.000
15:55637275:A:G	W840R	1.000
15:55637275:A:T	W840R	1.000
15:55677861:C:A	W439C	1.000
15:55677861:C:G	W439C	1.000
15:55677863:A:G	W439R	1.000
15:55677863:A:T	W439R	1.000
15:55680117:A:G	C304R	1.000
15:55680161:A:G	L289P	1.000
15:55680501:C:A	W268C	1.000
15:55680501:C:G	W268C	1.000
15:55680503:A:G	W268R	1.000
15:55680503:A:T	W268R	1.000
15:55682433:A:C	Y203D	1.000
15:55683825:C:A	W168C	1.000
15:55683825:C:G	W168C	1.000
15:55683827:A:G	W168R	1.000
15:55683827:A:T	W168R	1.000
15:55628944:A:C	I895R	0.999
15:55628944:A:T	I895K	0.999
15:55637273:C:A	W840C	0.999
15:55637273:C:G	W840C	0.999
15:55637274:C:G	W840S	0.999
15:55637280:A:T	V838D	0.999
15:55638617:A:T	V795D	0.999
15:55638623:A:G	F793S	0.999
15:55639742:A:G	W742R	0.999
15:55639742:A:T	W742R	0.999
15:55672528:A:G	L653P	0.999
15:55672574:A:G	W638R	0.999

dbSNP variants (sampled 300 via entrez): RS1000016155 (15:55671456 G>A), RS1000016587 (15:55691273 G>T), RS1000030533 (15:55624107 A>G), RS1000061945 (15:55659608 T>C), RS1000085823 (15:55708232 C>A), RS1000100251 (15:55666673 A>G), RS1000155601 (15:55655742 T>C), RS1000177001 (15:55734129 G>A), RS1000197404 (15:55695937 C>G,T), RS1000229965 (15:55679128 C>T), RS1000304954 (15:55684782 G>A,C), RS1000318428 (15:55618467 C>A,T), RS1000359475 (15:55673035 T>C), RS1000371672 (15:55612590 T>G), RS1000403122 (15:55690550 T>A,C)

Disease associations

OMIM: gene MIM:613261 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST002004_4	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)	9.000000e-07
GCST003998_13	Joint mobility (Beighton score)	1.000000e-08
GCST004713_7	Testicular germ cell tumor	1.000000e-11
GCST005580_89	Intraocular pressure	4.000000e-11
GCST007325_18	General risk tolerance (MTAG)	3.000000e-08
GCST007401_22	Factor VII activity	2.000000e-06
GCST010703_182	Brain morphology (MOSTest)	5.000000e-11
GCST012489_44	Heel bone mineral density x serum urate levels interaction	1.000000e-11

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0007905	joint hypermobility measurement
EFO:0004695	intraocular pressure measurement
EFO:0008579	risk-taking behaviour
EFO:0004619	factor VII measurement
EFO:0004346	neuroimaging measurement
EFO:0004531	urate measurement
EFO:0009270	heel bone mineral density

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, increases expression, affects expression	4
Ethanol	affects cotreatment, increases expression, decreases expression	3
Aflatoxin B1	decreases methylation, increases methylation	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	affects cotreatment, increases methylation	1
trichostatin A	increases expression	1
sodium arsenite	decreases expression	1
perfluorooctanoic acid	increases expression	1
aflatoxin B2	decreases methylation	1
nickel sulfate	increases expression	1
CGP 52608	increases reaction, affects binding	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
abrine	decreases expression	1
LDN 193189	affects cotreatment, increases expression	1
Fulvestrant	increases methylation, affects cotreatment	1
Leflunomide	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Carbamazepine	affects expression	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Folic Acid	affects cotreatment, increases expression	1
Lead	affects methylation	1
Nickel	decreases expression	1
Phthalic Acids	decreases methylation	1
Urethane	increases expression	1
Vanadates	decreases expression	1
Cyclosporine	decreases expression	1
Cadmium Chloride	decreases expression	1
Particulate Matter	increases abundance, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.